Draft monograph: orforglipron — submissions

Open-label extension data are presented alongside randomised data without distinction

The draft on Orforglipron was read in full. The respondent notes at the outset that this class has an unusually deep randomised evidence base, and that a monograph on it is fairly judged against a higher standard than one on a compound with none.

Long-term figures in the clinical section come from open-label extensions in which every participant received the active compound and those who did not tolerate it had already withdrawn. They are printed in the same table as randomised comparisons and in the same typeface.

The respondent proposes that extension data be presented in a separate table, or at minimum in a separately labelled block, and that the surviving-population problem be stated once where it arises.

The mechanism section is written with more confidence than the clinical section it precedes

The respondent submits on the draft monograph for Orforglipron. The observation arises from teaching the material rather than from prescribing it.

The pharmacology section states what the compound does at its receptor in the indicative mood and without hedging. The clinical section then reports that the effect has not been demonstrated in people. A reader who stops after the first section, as many will, takes away a claim the document goes on to withdraw.

The respondent does not propose that the pharmacology be hedged, which would be inaccurate, but that each pharmacology section close with a sentence stating which of the described actions has been shown to produce a clinical effect and which has not.

Quantitative claims are reproduced without the method that produced them

Having reviewed the draft on Orforglipron, the respondent makes a single submission, on the view that one point put clearly is more use to the secretariat than six put together.

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

The respondent has read submission 001 with interest and adds one observation the secretariat may find useful.

The absence of a rare harm in the trial set is presented as reassurance

This submission addresses the draft monograph on Orforglipron. The respondent went through the document twice, once as a specialist and once as a reader arriving without the background.

The draft states that a specific serious event was not observed in the contributing trials. The respondent states that trials of the size conducted here could not have detected an event at the frequency in question, and that reporting the absence without that arithmetic converts an uninformative result into a reassuring one.

The respondent proposes that the detectable frequency be stated wherever the absence of an event is reported.

This submission should be read alongside submission 003, which arises on the same draft.

The pharmacokinetic section does not connect half-life to the dosing schedule

The respondent works on cardiometabolic outcomes and read the draft on Orforglipron with that literature in view.

The draft reports a half-life and, separately, a dosing interval. The respondent, a clinical pharmacologist, states that the relationship between the two is what determines accumulation and time to steady state, and that the monograph leaves the reader to derive it.

The respondent proposes that time to steady state be stated explicitly, with the assumption from which it was derived.

The respondent has read submission 001 and puts a further matter to the secretariat.

What happens when the compound is stopped is not addressed

The respondent has read the draft monograph on Orforglipron against a caseload in which incretin analogues are prescribed daily.

The draft assesses the effect of the compound while it is being taken. The respondent, who declares having used a compound in the class under prescription, states that the question a person actually faces is what happens afterwards, and that the monograph is silent on it.

The respondent proposes that the trajectory after discontinuation be an assessed outcome wherever any contributing trial measured it, and a recorded evidence gap wherever none did.

A near-isobaric analogue is not distinguished by the identity determination described

The respondent read the draft on Orforglipron alongside the approved labelling for the class, and submits on one matter arising.

The identity determination described in the draft resolves the compound from unrelated substances but would not distinguish it from a closely related analogue whose mass differs by approximately one dalton.

The respondent proposes that the monograph state the resolution required for that discrimination, and state that a nominal-mass instrument reporting an integer mass has not made it.

The population to which the headline estimate applies is not stated with the estimate

The draft on Orforglipron is a substantial document and the respondent has confined this submission to one matter.

The draft carries a headline effect estimate in the abstract without the eligibility criteria of the trials that produced it. The respondent states that the estimate applies to a trial population with specific age, comorbidity and baseline criteria, and that a reader will apply it to whoever is in front of them.

The respondent proposes a one-line population statement adjacent to every headline estimate.

The respondent notes that submission 001 has already been made and confines this submission to a matter not covered by it.

What happens to weight after the compound is stopped is not in the assessed outcomes

This submission concerns Orforglipron and makes one point.

Several trials in the evidence base ran a withdrawal period and reported what happened. That evidence is the single most useful thing a person considering the compound could be told, and it appears in the monograph only as a sentence in the discussion.

The respondent proposes that post-withdrawal trajectory be an assessed outcome in its own right for every compound where a withdrawal period was studied, with its own certainty rating.

The respondent has read submission 001 above and makes this submission independently of it.

Glycaemic trials and weight-management trials are drawn on interchangeably

This is a submission on the draft covering Orforglipron, from a respondent whose work is with the people taking compounds of this class rather than with the trials that produced them.

The compound has two trial programmes with different populations, different doses and different endpoints. The monograph draws on both without saying which programme a given estimate came from, so a reader takes a weight figure obtained at one dose in one population as though it applied at the other.

The respondent proposes that the programme be named against every effect estimate in the assessed-outcome table.

Submission 006 raises an adjacent matter. The respondent regards the two as separable and addresses only this one.